Skip to main content
Fig. 4 | Journal of Experimental & Clinical Cancer Research

Fig. 4

From: Combinational blockade of MET and PD-L1 improves pancreatic cancer immunotherapeutic efficacy

Fig. 4

MET maintains PD-L1 expression in PDAC cells. A and B Human BXPC3 (A) and mouse KPC (B) PDAC cell lines are transfected with MET-silenced (shMET) and negative control (CTRL) vectors, respectively; MET and PD-L1 levels are assessed by immunoblotting. C Cell-surface PD-L1 expressions as assessed by flow cytometry in BXPC3 cells (up), with quantification (down). D Cell-surface PD-L1 expressions as assessed by flow cytometry in KPC cells (up), with quantification (down). E and F PD-L1 expressions as assessed by Western blotting analysis in BXPC3 (E) and KPC (F) cells after a dose-increasing treatment with capmatinib. G and H Endogenous co-immunoprecipitation of BXPC3 cells (G) and KPC cells (H) by MET and PD-L1 antibodies. MET and PD-L1 expression levels are analyzed by Western blotting

Back to article page